ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study

Luca Moscetti, Lucia Mentuccia, Patrizia Vici, Silvia Quadrini, Isabella Sperduti, Laura Pizzuti, Maria Agnese Fabbri, Angela Vaccaro, Marcello Maugeri-Saccà, Maddalena Barba, Domenico Sergi, Germano Zampa, Teresa Gamucci

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

AIM: Quality of life (QoL) is a critical issue for women with metastatic breast cancer (MBC). Eribulin mesylate represents a novel and active drug for pretreated MBC. Regretfully, few data exploring health-related (HR) QoL are available in unselected populations.

PATIENTS & METHODS: A multicenter prospective observational study was conducted in 50 MBC patients treated with eribulin mesylate, in order to evaluate HRQoL and patients' well-being by using the Edmonton symptoms assessment scale (ESAS) and Functional Assessment of Cancer Therapy-Breast questionnaires.

RESULTS: A significant ESAS score improvement was observed with a 10% median decrease. No differences were revealed for the QoL scores.

CONCLUSION: The analysis of ESAS and Functional Assessment of Cancer Therapy scores showed that eribulin mesylate contributes to preserve QoL in MBC patients.

Original languageEnglish
Pages (from-to)1517-1525
Number of pages9
JournalFuture Oncology
Volume13
Issue number17
DOIs
Publication statusPublished - Jul 2017

Fingerprint

eribulin
Symptom Assessment
Multicenter Studies
Observational Studies
Prospective Studies
Breast Neoplasms
Quality of Life

Keywords

  • Journal Article

Cite this

ESAS and FACT-B in eribulin-treated metastatic breast cancer patients : a multicenter, prospective and observational study. / Moscetti, Luca; Mentuccia, Lucia; Vici, Patrizia; Quadrini, Silvia; Sperduti, Isabella; Pizzuti, Laura; Fabbri, Maria Agnese; Vaccaro, Angela; Maugeri-Saccà, Marcello; Barba, Maddalena; Sergi, Domenico; Zampa, Germano; Gamucci, Teresa.

In: Future Oncology, Vol. 13, No. 17, 07.2017, p. 1517-1525.

Research output: Contribution to journalArticle

Moscetti, L, Mentuccia, L, Vici, P, Quadrini, S, Sperduti, I, Pizzuti, L, Fabbri, MA, Vaccaro, A, Maugeri-Saccà, M, Barba, M, Sergi, D, Zampa, G & Gamucci, T 2017, 'ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study', Future Oncology, vol. 13, no. 17, pp. 1517-1525. https://doi.org/10.2217/fon-2017-0062
Moscetti, Luca ; Mentuccia, Lucia ; Vici, Patrizia ; Quadrini, Silvia ; Sperduti, Isabella ; Pizzuti, Laura ; Fabbri, Maria Agnese ; Vaccaro, Angela ; Maugeri-Saccà, Marcello ; Barba, Maddalena ; Sergi, Domenico ; Zampa, Germano ; Gamucci, Teresa. / ESAS and FACT-B in eribulin-treated metastatic breast cancer patients : a multicenter, prospective and observational study. In: Future Oncology. 2017 ; Vol. 13, No. 17. pp. 1517-1525.
@article{d80207650ec849ffb2d505e5b2de9e1d,
title = "ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study",
abstract = "AIM: Quality of life (QoL) is a critical issue for women with metastatic breast cancer (MBC). Eribulin mesylate represents a novel and active drug for pretreated MBC. Regretfully, few data exploring health-related (HR) QoL are available in unselected populations.PATIENTS & METHODS: A multicenter prospective observational study was conducted in 50 MBC patients treated with eribulin mesylate, in order to evaluate HRQoL and patients' well-being by using the Edmonton symptoms assessment scale (ESAS) and Functional Assessment of Cancer Therapy-Breast questionnaires.RESULTS: A significant ESAS score improvement was observed with a 10{\%} median decrease. No differences were revealed for the QoL scores.CONCLUSION: The analysis of ESAS and Functional Assessment of Cancer Therapy scores showed that eribulin mesylate contributes to preserve QoL in MBC patients.",
keywords = "Journal Article",
author = "Luca Moscetti and Lucia Mentuccia and Patrizia Vici and Silvia Quadrini and Isabella Sperduti and Laura Pizzuti and Fabbri, {Maria Agnese} and Angela Vaccaro and Marcello Maugeri-Sacc{\`a} and Maddalena Barba and Domenico Sergi and Germano Zampa and Teresa Gamucci",
year = "2017",
month = "7",
doi = "10.2217/fon-2017-0062",
language = "English",
volume = "13",
pages = "1517--1525",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "17",

}

TY - JOUR

T1 - ESAS and FACT-B in eribulin-treated metastatic breast cancer patients

T2 - a multicenter, prospective and observational study

AU - Moscetti, Luca

AU - Mentuccia, Lucia

AU - Vici, Patrizia

AU - Quadrini, Silvia

AU - Sperduti, Isabella

AU - Pizzuti, Laura

AU - Fabbri, Maria Agnese

AU - Vaccaro, Angela

AU - Maugeri-Saccà, Marcello

AU - Barba, Maddalena

AU - Sergi, Domenico

AU - Zampa, Germano

AU - Gamucci, Teresa

PY - 2017/7

Y1 - 2017/7

N2 - AIM: Quality of life (QoL) is a critical issue for women with metastatic breast cancer (MBC). Eribulin mesylate represents a novel and active drug for pretreated MBC. Regretfully, few data exploring health-related (HR) QoL are available in unselected populations.PATIENTS & METHODS: A multicenter prospective observational study was conducted in 50 MBC patients treated with eribulin mesylate, in order to evaluate HRQoL and patients' well-being by using the Edmonton symptoms assessment scale (ESAS) and Functional Assessment of Cancer Therapy-Breast questionnaires.RESULTS: A significant ESAS score improvement was observed with a 10% median decrease. No differences were revealed for the QoL scores.CONCLUSION: The analysis of ESAS and Functional Assessment of Cancer Therapy scores showed that eribulin mesylate contributes to preserve QoL in MBC patients.

AB - AIM: Quality of life (QoL) is a critical issue for women with metastatic breast cancer (MBC). Eribulin mesylate represents a novel and active drug for pretreated MBC. Regretfully, few data exploring health-related (HR) QoL are available in unselected populations.PATIENTS & METHODS: A multicenter prospective observational study was conducted in 50 MBC patients treated with eribulin mesylate, in order to evaluate HRQoL and patients' well-being by using the Edmonton symptoms assessment scale (ESAS) and Functional Assessment of Cancer Therapy-Breast questionnaires.RESULTS: A significant ESAS score improvement was observed with a 10% median decrease. No differences were revealed for the QoL scores.CONCLUSION: The analysis of ESAS and Functional Assessment of Cancer Therapy scores showed that eribulin mesylate contributes to preserve QoL in MBC patients.

KW - Journal Article

U2 - 10.2217/fon-2017-0062

DO - 10.2217/fon-2017-0062

M3 - Article

C2 - 28429617

VL - 13

SP - 1517

EP - 1525

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 17

ER -